• Thurs news: Novartis not joining weight loss race. Pharma marketing and climate change. Roche flu treatment trial. Cercle’s fund raise for women’s health. ICER looks at GSK COPD drugs. See more on our front page

We'Re An OnCoLoGy CoMpAnY





What kind of morons hang their hats on Chinese manufacturing these days?


Junshi Biosciences and Coherus Share Update on the FDA Review of the Biologics License Application (BLA) for Toripalimab as Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC) | BioSpace

https://www.biospace.com/article/re...-or-metastatic-nasopharyngeal-carcinoma-npc-/

  • FDA has been unable to travel to China to conduct the required site inspection resulting in delayed action on the BLA
  • Junshi Biosciences and Coherus are actively engaged in ongoing discussions with the FDA to support the inspections and gain approval of toripalimab for patients with NPC in the U.S. as quickly as possible
 




























































“Importantly, it focuses our commercial and marketing efforts singularly in oncology where we project continued growth,” Lanfear said [on the sale of Cimerli].

What a joke. A me too pd1 and Dimmy actually thinks we're gonna be a player. This leadership team has delusions of grandeur. We're going to be about as much of an oncology Company as SS is an astronaut...if we're even still a company at all in year.